转移性三阴性乳腺癌-话题@MedSci

#转移性三阴性乳腺癌#

20篇内容 | 633人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2028645, encodeId=9e692028645aa, content=<a href='/topic/show?id=672a9340235' target=_blank style='color:#2F92EE;'>#转移性三阴性乳腺癌#</a>, objectTitle=Nat Commun：复旦大学王碧芸/胡夕春团队发现转移性三阴性乳腺癌的高效联合化疗方案, objectType=article, longId=733030, objectId=73fbe3303097, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73fbe3303097, replyNumber=0, likeNumber=46, createdTime=2023-06-07, rootId=0, userName=小刀医生, userId=8306486, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73fbe3303097, moduleTitle=Nat Commun：复旦大学王碧芸/胡夕春团队发现转移性三阴性乳腺癌的高效联合化疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73fbe3303097)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028646, encodeId=a9ab2028646ef, content=<a href='/topic/show?id=672a9340235' target=_blank style='color:#2F92EE;'>#转移性三阴性乳腺癌#</a>, objectTitle=Dato-DXd针对转移性三阴性乳腺癌的3期临床试验启动，结果令人期待！, objectType=article, longId=737158, objectId=579ee371587c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=579ee371587c, replyNumber=0, likeNumber=53, createdTime=2023-03-31, rootId=0, userName=小刀医生, userId=8306486, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=579ee371587c, moduleTitle=Dato-DXd针对转移性三阴性乳腺癌的3期临床试验启动，结果令人期待！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=579ee371587c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028644, encodeId=6022202864487, content=<a href='/topic/show?id=672a9340235' target=_blank style='color:#2F92EE;'>#转移性三阴性乳腺癌#</a>, objectTitle=Ann Oncol:紫杉醇联合或不联合atezolizumab一线治疗不可切除、局部晚期或转移性三阴性乳腺癌的疗效: IMpassion131初次分析, objectType=article, longId=213741, objectId=328f213e41bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=328f213e41bd, replyNumber=0, likeNumber=0, createdTime=2021-10-17, rootId=0, userName=小刀医生, userId=8306486, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=328f213e41bd, moduleTitle=Ann Oncol:紫杉醇联合或不联合atezolizumab一线治疗不可切除、局部晚期或转移性三阴性乳腺癌的疗效: IMpassion131初次分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=328f213e41bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028643, encodeId=00532028643bb, content=<a href='/topic/show?id=672a9340235' target=_blank style='color:#2F92EE;'>#转移性三阴性乳腺癌#</a>, objectTitle=Ann Oncol: atezolizumab联合白蛋白结合型紫杉醇一线治疗不可切除、局部晚期或转移性三阴性乳腺癌的疗效: IMpassion130最终总生存分析, objectType=article, longId=213736, objectId=41a6213e36ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41a6213e36ec, replyNumber=0, likeNumber=49, createdTime=2021-08-04, rootId=0, userName=小刀医生, userId=8306486, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41a6213e36ec, moduleTitle=Ann Oncol: atezolizumab联合白蛋白结合型紫杉醇一线治疗不可切除、局部晚期或转移性三阴性乳腺癌的疗效: IMpassion130最终总生存分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41a6213e36ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028639, encodeId=5074202863997, content=<a href='/topic/show?id=672a9340235' target=_blank style='color:#2F92EE;'>#转移性三阴性乳腺癌#</a>, objectTitle=Lancet：派姆单抗联合化疗一线治疗PD-L1阳性转移性三阴性乳腺癌, objectType=article, longId=204210, objectId=9f312042101b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f312042101b, replyNumber=0, likeNumber=0, createdTime=2021-06-30, rootId=0, userName=小刀医生, userId=8306486, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f312042101b, moduleTitle=Lancet：派姆单抗联合化疗一线治疗PD-L1阳性转移性三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f312042101b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028642, encodeId=73a22028642cb, content=<a href='/topic/show?id=672a9340235' target=_blank style='color:#2F92EE;'>#转移性三阴性乳腺癌#</a>, objectTitle=NEJM：ADC药物Sacituzumab govitecan一线治疗转移性三阴性乳腺癌, objectType=article, longId=210410, objectId=eb7421041030, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb7421041030, replyNumber=0, likeNumber=38, createdTime=2021-10-11, rootId=0, userName=小刀医生, userId=8306486, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb7421041030, moduleTitle=NEJM：ADC药物Sacituzumab govitecan一线治疗转移性三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb7421041030)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028641, encodeId=2d6120286413c, content=<a href='/topic/show?id=672a9340235' target=_blank style='color:#2F92EE;'>#转移性三阴性乳腺癌#</a>, objectTitle=Clin Cancer Res：艾立布林联合帕博利珠单抗对转移性三阴性乳腺癌有效, objectType=article, longId=208835, objectId=da3a20883514, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da3a20883514, replyNumber=0, likeNumber=38, createdTime=2021-08-29, rootId=0, userName=小刀医生, userId=8306486, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da3a20883514, moduleTitle=Clin Cancer Res：艾立布林联合帕博利珠单抗对转移性三阴性乳腺癌有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da3a20883514)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028640, encodeId=ec0b2028640d8, content=<a href='/topic/show?id=672a9340235' target=_blank style='color:#2F92EE;'>#转移性三阴性乳腺癌#</a>, objectTitle=Lancet oncol：3期| 派姆单抗用作转移性三阴性乳腺癌的二三线疗法的疗效, objectType=article, longId=207920, objectId=b4f120e9205b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4f120e9205b, replyNumber=0, likeNumber=35, createdTime=2021-07-08, rootId=0, userName=小刀医生, userId=8306486, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4f120e9205b, moduleTitle=Lancet oncol：3期| 派姆单抗用作转移性三阴性乳腺癌的二三线疗法的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4f120e9205b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028637, encodeId=fc0c202863eda, content=<a href='/topic/show?id=672a9340235' target=_blank style='color:#2F92EE;'>#转移性三阴性乳腺癌#</a>, objectTitle=转移性三阴性乳腺癌治疗获突破：性抗体偶联疗法疗效显著, objectType=article, longId=192310, objectId=61191923102d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61191923102d, replyNumber=0, likeNumber=40, createdTime=2021-03-29, rootId=0, userName=小刀医生, userId=8306486, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61191923102d, moduleTitle=转移性三阴性乳腺癌治疗获突破：性抗体偶联疗法疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61191923102d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028636, encodeId=6662202863640, content=<a href='/topic/show?id=672a9340235' target=_blank style='color:#2F92EE;'>#转移性三阴性乳腺癌#</a>, objectTitle=FDA接受Sacituzumab Govitecan治疗转移性三阴性乳腺癌的BLA, objectType=article, longId=185333, objectId=36af18533328, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36af18533328, replyNumber=0, likeNumber=0, createdTime=2020-07-08, rootId=0, userName=小刀医生, userId=8306486, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36af18533328, moduleTitle=FDA接受Sacituzumab Govitecan治疗转移性三阴性乳腺癌的BLA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36af18533328)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028638, encodeId=8f1d202863851, content=<a href='/topic/show?id=672a9340235' target=_blank style='color:#2F92EE;'>#转移性三阴性乳腺癌#</a>, objectTitle=抗体药物偶联物DS-1062研究范围被扩大，治疗晚期或转移性三阴性乳腺癌, objectType=article, longId=196920, objectId=36881969209a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36881969209a, replyNumber=0, likeNumber=40, createdTime=2021-05-03, rootId=0, userName=小刀医生, userId=8306486, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36881969209a, moduleTitle=抗体药物偶联物DS-1062研究范围被扩大，治疗晚期或转移性三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36881969209a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028633, encodeId=67bd20286335f, content=<a href='/topic/show?id=672a9340235' target=_blank style='color:#2F92EE;'>#转移性三阴性乳腺癌#</a>, objectTitle=NEJM：sacituzumab govitecan-hziy治疗难治性转移性三阴性乳腺癌, objectType=article, longId=160705, objectId=9197160e05e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9197160e05e2, replyNumber=0, likeNumber=33, createdTime=2019-06-03, rootId=0, userName=小刀医生, userId=8306486, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9197160e05e2, moduleTitle=NEJM：sacituzumab govitecan-hziy治疗难治性转移性三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9197160e05e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028635, encodeId=6a03202863502, content=<a href='/topic/show?id=672a9340235' target=_blank style='color:#2F92EE;'>#转移性三阴性乳腺癌#</a>, objectTitle=Intensity的INT230-6获得FDA的快速通道指定，用于治疗复发或转移性三阴性乳腺癌, objectType=article, longId=164505, objectId=a10e164505e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a10e164505e1, replyNumber=0, likeNumber=41, createdTime=2019-09-02, rootId=0, userName=小刀医生, userId=8306486, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a10e164505e1, moduleTitle=Intensity的INT230-6获得FDA的快速通道指定，用于治疗复发或转移性三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a10e164505e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028632, encodeId=b2a42028632fe, content=<a href='/topic/show?id=672a9340235' target=_blank style='color:#2F92EE;'>#转移性三阴性乳腺癌#</a>, objectTitle=ANN ONCOL：蛋白结合型紫杉醇联合卡铂或吉西他滨治疗转移性三阴性乳腺癌, objectType=article, longId=147408, objectId=1ea914e40885, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ea914e40885, replyNumber=0, likeNumber=46, createdTime=2019-02-09, rootId=0, userName=小刀医生, userId=8306486, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ea914e40885, moduleTitle=ANN ONCOL：蛋白结合型紫杉醇联合卡铂或吉西他滨治疗转移性三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ea914e40885)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028634, encodeId=80c8202863468, content=<a href='/topic/show?id=672a9340235' target=_blank style='color:#2F92EE;'>#转移性三阴性乳腺癌#</a>, objectTitle=“智能药物”显示出转移性三阴性乳腺癌的治疗前景, objectType=article, longId=161063, objectId=ec89161063e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec89161063e5, replyNumber=0, likeNumber=47, createdTime=2019-05-10, rootId=0, userName=小刀医生, userId=8306486, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec89161063e5, moduleTitle=“智能药物”显示出转移性三阴性乳腺癌的治疗前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec89161063e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028630, encodeId=53132028630ae, content=<a href='/topic/show?id=672a9340235' target=_blank style='color:#2F92EE;'>#转移性三阴性乳腺癌#</a>, objectTitle=Lancet oncol：Ipatasertib联合紫杉醇对转移性三阴性乳腺癌的治疗效果。, objectType=article, longId=108170, objectId=23731081e014, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=23731081e014, replyNumber=0, likeNumber=41, createdTime=2018-06-13, rootId=0, userName=小刀医生, userId=8306486, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=23731081e014, moduleTitle=Lancet oncol：Ipatasertib联合紫杉醇对转移性三阴性乳腺癌的治疗效果。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=23731081e014)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028631, encodeId=9cff202863187, content=<a href='/topic/show?id=672a9340235' target=_blank style='color:#2F92EE;'>#转移性三阴性乳腺癌#</a>, objectTitle=J Clin Oncol：外周血cfDNA中的肿瘤分数可以预测转移性三阴性乳腺癌的预后, objectType=article, longId=125829, objectId=a23912582962, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a23912582962, replyNumber=0, likeNumber=48, createdTime=2018-09-29, rootId=0, userName=小刀医生, userId=8306486, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a23912582962, moduleTitle=J Clin Oncol：外周血cfDNA中的肿瘤分数可以预测转移性三阴性乳腺癌的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a23912582962)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028629, encodeId=0b942028629cb, content=<a href='/topic/show?id=672a9340235' target=_blank style='color:#2F92EE;'>#转移性三阴性乳腺癌#</a>, objectTitle=邸立军：转移性三阴性乳腺癌全新治疗进展, objectType=article, longId=51137, objectId=96875113eb4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96875113eb4, replyNumber=0, likeNumber=32, createdTime=2016-02-19, rootId=0, userName=小刀医生, userId=8306486, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96875113eb4, moduleTitle=邸立军：转移性三阴性乳腺癌全新治疗进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96875113eb4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028628, encodeId=a1ac20286280c, content=<a href='/topic/show?id=672a9340235' target=_blank style='color:#2F92EE;'>#转移性三阴性乳腺癌#</a>, objectTitle=Clin Cancer Res：辅助转移性三阴性乳腺癌预后分析, objectType=article, longId=44735, objectId=b1bf44e3560, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1bf44e3560, replyNumber=0, likeNumber=38, createdTime=2015-04-14, rootId=0, userName=小刀医生, userId=8306486, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1bf44e3560, moduleTitle=Clin Cancer Res：辅助转移性三阴性乳腺癌预后分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1bf44e3560)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028627, encodeId=7d36202862e1b, content=<a href='/topic/show?id=672a9340235' target=_blank style='color:#2F92EE;'>#转移性三阴性乳腺癌#</a>, objectTitle=ESMO 2014：吉西他滨联合顺铂(GP)或紫杉醇(GT)一线治疗复发或转移性三阴性乳腺癌获良好疗效(CBCSG006试验), objectType=article, longId=40873, objectId=e833408e36f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e833408e36f, replyNumber=0, likeNumber=42, createdTime=2014-12-24, rootId=0, userName=小刀医生, userId=8306486, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e833408e36f, moduleTitle=ESMO 2014：吉西他滨联合顺铂(GP)或紫杉醇(GT)一线治疗复发或转移性三阴性乳腺癌获良好疗效(CBCSG006试验), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e833408e36f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

转移性三阴性乳腺癌

2020-05-29

小刀医生 (审核中...)

前往app查看评论内容

#转移性三阴性乳腺癌#

Nat Commun：复旦大学王碧芸/胡夕春团队发现转移性三阴性乳腺癌的高效联合化疗方案

2023-06-07

小刀医生 (审核中...)

前往app查看评论内容

#转移性三阴性乳腺癌#

Dato-DXd针对转移性三阴性乳腺癌的3期临床试验启动，结果令人期待！

2023-03-31

小刀医生 (审核中...)

前往app查看评论内容

#转移性三阴性乳腺癌#

Ann Oncol:紫杉醇联合或不联合atezolizumab一线治疗不可切除、局部晚期或转移性三阴性乳腺癌的疗效: IMpassion131初次分析

2021-10-17

小刀医生 (审核中...)

前往app查看评论内容

#转移性三阴性乳腺癌#

Ann Oncol: atezolizumab联合白蛋白结合型紫杉醇一线治疗不可切除、局部晚期或转移性三阴性乳腺癌的疗效: IMpassion130最终总生存分析

2021-08-04

小刀医生 (审核中...)

前往app查看评论内容

#转移性三阴性乳腺癌#

Lancet：派姆单抗联合化疗一线治疗PD-L1阳性转移性三阴性乳腺癌

2021-06-30

小刀医生 (审核中...)

前往app查看评论内容

#转移性三阴性乳腺癌#

NEJM：ADC药物Sacituzumab govitecan一线治疗转移性三阴性乳腺癌

2021-10-11

小刀医生 (审核中...)

前往app查看评论内容

#转移性三阴性乳腺癌#

Clin Cancer Res：艾立布林联合帕博利珠单抗对转移性三阴性乳腺癌有效

2021-08-29

小刀医生 (审核中...)

前往app查看评论内容

#转移性三阴性乳腺癌#

Lancet oncol：3期| 派姆单抗用作转移性三阴性乳腺癌的二三线疗法的疗效

2021-07-08

小刀医生 (审核中...)

前往app查看评论内容

#转移性三阴性乳腺癌#

转移性三阴性乳腺癌治疗获突破：性抗体偶联疗法疗效显著

2021-03-29

小刀医生 (审核中...)

前往app查看评论内容

#转移性三阴性乳腺癌#

FDA接受Sacituzumab Govitecan治疗转移性三阴性乳腺癌的BLA

2020-07-08

小刀医生 (审核中...)

前往app查看评论内容

#转移性三阴性乳腺癌#

抗体药物偶联物DS-1062研究范围被扩大，治疗晚期或转移性三阴性乳腺癌

2021-05-03

小刀医生 (审核中...)

前往app查看评论内容

#转移性三阴性乳腺癌#

NEJM：sacituzumab govitecan-hziy治疗难治性转移性三阴性乳腺癌

2019-06-03

小刀医生 (审核中...)

前往app查看评论内容

#转移性三阴性乳腺癌#

Intensity的INT230-6获得FDA的快速通道指定，用于治疗复发或转移性三阴性乳腺癌

2019-09-02

小刀医生 (审核中...)

前往app查看评论内容

#转移性三阴性乳腺癌#

ANN ONCOL：蛋白结合型紫杉醇联合卡铂或吉西他滨治疗转移性三阴性乳腺癌

2019-02-09

小刀医生 (审核中...)

前往app查看评论内容

#转移性三阴性乳腺癌#

“智能药物”显示出转移性三阴性乳腺癌的治疗前景

2019-05-10

小刀医生 (审核中...)

前往app查看评论内容

#转移性三阴性乳腺癌#

Lancet oncol：Ipatasertib联合紫杉醇对转移性三阴性乳腺癌的治疗效果。

2018-06-13

小刀医生 (审核中...)

前往app查看评论内容

#转移性三阴性乳腺癌#

J Clin Oncol：外周血cfDNA中的肿瘤分数可以预测转移性三阴性乳腺癌的预后

2018-09-29

小刀医生 (审核中...)

前往app查看评论内容

#转移性三阴性乳腺癌#

邸立军：转移性三阴性乳腺癌全新治疗进展

2016-02-19

小刀医生 (审核中...)

前往app查看评论内容

#转移性三阴性乳腺癌#

Clin Cancer Res：辅助转移性三阴性乳腺癌预后分析

2015-04-14

小刀医生 (审核中...)

前往app查看评论内容

#转移性三阴性乳腺癌#

ESMO 2014：吉西他滨联合顺铂(GP)或紫杉醇(GT)一线治疗复发或转移性三阴性乳腺癌获良好疗效(CBCSG006试验)

2014-12-24

科室
- - 订阅+
  - 更多科室
工具
服务